Carlo Iavarone
About
Carlo Iavarone is from Greater Boston. Carlo works in the following industries: "Pharmaceutical Manufacturing". Carlo is currently Senior Director Pre-Clinical at Celsion Corporation. In Carlo's previous role as a Scientific consultant at -, Carlo worked in until Apr 2021. Prior to joining -, Carlo was a Senior Research Scientist at GSK US and held the position of Senior Research Scientist at Rockville, Maryland. Prior to that, Carlo was a Expert Scientist at GSK US, based in Cambridge US from Mar 2015 to Dec 2018. Carlo started working as Investigator II at Novartis in Cambridge US in Mar 2011. From Jan 2009 to Jan 2011, Carlo was Investigator I at Novartis, based in Cambridge US. Prior to that, Carlo was a Post doctoral Fellow at Novartis Vaccines and Diagnostics, based in Siena Italy from Jan 2007 to Jan 2009. Carlo started working as Post doctoral Fellow MIUR PRIN at Universita' di Napoli "FedericoII" in II Policlinico - Napoli in Jan 2006.
Carlo Iavarone's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Carlo Iavarone's current jobs
DNA Vaccine Platform Preclinical. Ovarian cancer gene therapy: clinical phase II, translational studies
Carlo Iavarone's past jobs
In vivo and in vitro immune cells activation and proliferation with small molecules immunopotentiator (PRRs: TLRs, STING, RLRs). Antigen identification. SAM vaccine. Adeno vaccine. Vaccine vectors characterization and improvement. Science advisor - Allergies type I, CRISPR
Melanoma cancer immunotherapy leadership. CTL response. Melanoma efficacy studies. Characterization of novel vaccine technologies: RNA vaccine. Leadership combo RNA vaccine with compounds to improve the vaccine potency.
Characterization of novel vaccine technologies. Molecular Target Identification team (receptor and compound MOA studies, hit re-confirmation and follow up). In vivo studies with adjuvants, SMIPs, proteins: T-cells and B-cells evaluation
Characterization of novel vaccine technologies and adjuvants. Drug discovery. Molecular Target Identification team (receptor and compound MOA studies, hit re-confirmation and follow up).
Identifictation of MAPK ERK8 interactors by yeast two-hybrid screening.
Tyrosine kinase PDGF receptor and JNK role in c-myc transcription, identification of AP-1 responsive element in c-myc promoter. Activation of atypical MAPK ERK8 by tyrosine kinase proto-oncogene RET/PTC3. Tyrosine kinase PDGF receptor role in HDACs activity.
Discovered PAGE4 expression, evaulation as target for prostate cancer vaccine Identification of two novel genes: MRP9 highly expressed in breast cancer and PATE expressed in prostate cancer, evaluation as targets for immunotherapy.
Tyrosine kinase EGF receptor